1. inability to comprehend and to follow all required study procedures. 2. allergy or severe reactions to the study drugs 3. patients with known prolonged qt or pr interval, second- or third-degree heart block, or ventricular cardiac arrhythmias, including torsade de pointes 4. patients taking medication that will potentially interact with lopinavir/ ritonavir, ribavirin or interferon-beta1b 5. patients with known history of severe depression 6. pregnant or lactation women 7. inability to comprehend and to follow all required study procedures 8. received an experimental agent (vaccine, drug, biologic, device, blood product, or medication) within 1 month prior to recruitment in this study or expect to receive an experimental agent during this study. unwilling to refuse participation in another clinical study through the end of this study. 9. have a history of alcohol or drug abuse in the last 5 years. 10. have any condition that the investigator believes may interfere with successful completion of the study.

1. inability to comprehend and to follow all required study procedures. 2. allergy or severe reactions to the study drugs 3. patients with known prolonged qt or pr interval, second- or third-degree heart block, or ventricular cardiac arrhythmias, including torsade de pointes 4. patients taking medication that will potentially interact with lopinavir/ ritonavir, ribavirin or interferon-beta1b 5. patients with known history of severe depression 6. pregnant or lactation women 7. inability to comprehend and to follow all required study procedures 8. received an experimental agent (vaccine, drug, biologic, device, blood product, or medication) within 1 month prior to recruitment in this study or expect to receive an experimental agent during this study. unwilling to refuse participation in another clinical study through the end of this study. 9. have a history of alcohol or drug abuse in the last 5 years. 10. have any condition that the investigator believes may interfere with successful completion of the study.

inability to comprehend and to follow all required study procedures. allergy or severe reactions to the study drugs patients with known prolonged qt or pr interval, second- or third-degree heart block, or ventricular cardiac arrhythmias, including torsade de pointes patients taking medication that will potentially interact with lopinavir/ ritonavir, ribavirin or interferon-beta1b patients with known history of severe depression pregnant or lactation women inability to comprehend and to follow all required study procedures received an experimental agent (vaccine, drug, biologic, device, blood product, or medication) within 1 month prior to recruitment in this study or expect to receive an experimental agent during this study. unwilling to refuse participation in another clinical study through the end of this study. have a history of alcohol or drug abuse in the last 5 years. have any condition that the investigator believes may interfere with successful completion of the study.

inability to comprehend and to follow all required study procedures. allergy or severe reactions to the study drugs patients with known prolonged qt or pr interval, second- or third-degree heart block, or ventricular cardiac arrhythmias, including torsade de pointes patients taking medication that will potentially interact with lopinavir/ ritonavir, ribavirin or interferon-beta1b patients with known history of severe depression pregnant or lactation women inability to comprehend and to follow all required study procedures received an experimental agent (vaccine, drug, biologic, device, blood product, or medication) within 1 month prior to recruitment in this study or expect to receive an experimental agent during this study. unwilling to refuse participation in another clinical study through the end of this study. have a history of alcohol or drug abuse in the last 5 years. have any condition that the investigator believes may interfere with successful completion of the study.

1. inability to comprehend and to follow all required study procedures. 2. allergy or severe reactions to the study drugs 3. patients with known prolonged qt or pr interval, second- or third-degree heart block, or ventricular cardiac arrhythmias, including torsade de pointes 4. patients taking medication that will potentially interact with lopinavir/ ritonavir, ribavirin or interferon-beta1b 5. patients with known history of severe depression 6. pregnant or lactation women 7. inability to comprehend and to follow all required study procedures 8. received an experimental agent (vaccine, drug, biologic, device, blood product, or medication) within 1 month prior to recruitment in this study or expect to receive an experimental agent during this study. unwilling to refuse participation in another clinical study through the end of this study. 9. have a history of alcohol or drug abuse in the last 5 years. 10. have any condition that the investigator believes may interfere with successful completion of the study.

1. inability to comprehend and to follow all required study procedures. 2. allergy or severe reactions to the study drugs 3. patients with known prolonged qt or pr interval, second- or third-degree heart block, or ventricular cardiac arrhythmias, including torsade de pointes 4. patients taking medication that will potentially interact with lopinavir/ ritonavir, ribavirin or interferon-beta1b 5. patients with known history of severe depression 6. pregnant or lactation women 7. inability to comprehend and to follow all required study procedures 8. received an experimental agent (vaccine, drug, biologic, device, blood product, or medication) within 1 month prior to recruitment in this study or expect to receive an experimental agent during this study. unwilling to refuse participation in another clinical study through the end of this study. 9. have a history of alcohol or drug abuse in the last 5 years. 10. have any condition that the investigator believes may interfere with successful completion of the study.